enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Pegcetacoplan - Wikipedia

    en.wikipedia.org/wiki/Pegcetacoplan

    Pegcetacoplan is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3. [9] Pegcetacoplan was approved for medical use in the United States in May 2021. [9] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [16]

  3. The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.

  4. Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in ...

    lite.aol.com/tech/story/0022/20250127/9348133.htm

    WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ® (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by ...

  5. PDUFA date - Wikipedia

    en.wikipedia.org/wiki/PDUFA_date

    The PDUFA date serves as a good first approximation of when a final decision on drug approval can be expected. Sponsors frequently publish PDUFA dates for their pending applications, [1] and while there is no official list of PDUFA dates, [10] several websites collect PDUFA dates from press announcements in a calendar form.

  6. ATC code L04 - Wikipedia

    en.wikipedia.org/wiki/ATC_code_L04

    ATC code L04 Immunosuppressants is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.

  7. Iptacopan - Wikipedia

    en.wikipedia.org/wiki/Iptacopan

    Iptacopan was approved by the US Food and Drug Administration (FDA) for the treatment of adults with paroxysmal nocturnal hemoglobinuria in December 2023. [6] [7] The FDA considers it to be a first-in-class medication. [8]

  8. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...

  9. File:Pegcetacoplan v01.svg - Wikipedia

    en.wikipedia.org/wiki/File:Pegcetacoplan_v01.svg

    Click on a date/time to view the file as it appeared at that time. Date/Time Thumbnail ... Pegcetacoplan; Global file usage. The following other wikis use this file: